default author photo

Takao Hashiguchi

Kyushu University - Department of Virology

6-19-1, Hakozaki, Higashiku

Fukuoka, Fukuoka 812-8581

Japan

SCHOLARLY PAPERS

2

DOWNLOADS

87

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Broad Neutralization Activity of SARS-CoV-2 Antibody is Achieved by Coordinated Recognition of Virus Vulnerable Site

Number of pages: 52 Posted: 01 Apr 2021
National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Hokkaido University - Laboratory of Biomolecular Science, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Hokkaido University - Division of Molecular Pathobiology, Hokkaido University - Center for Research and Education on Drug Discovery, Osaka University - Laboratory of Lymphocyte Differentiation, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Division of Molecular Pathobiology, Hokkaido University - Division of Molecular Pathobiology, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Pathology, Kyushu University - Department of Virology, Kyushu University - Department of Virology, National Institute of Infectious Diseases - Pathogen Genomic Center, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Department of Virology I, Tottori University - Chromosome Engineering Research Center, Tottori University - Chromosome Engineering Research Center, National Institute of Infectious Diseases - Department of Immunology, Trans Chromosomics Inc., Osaka University - Laboratory of Lymphocyte Differentiation, National Institute of Infectious Diseases - Pathogen Genomic Center, National Institute of Infectious Diseases - Department of Pathology, Hokkaido University - Division of Molecular Pathobiology, Kyushu University - Department of Virology, Hokkaido University - Laboratory of Biomolecular Science and National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development
Downloads 49 (1,074,648)

Abstract:

Loading...

2.

Identification of Anti-COVID-19 Agents, Cepharanthine and Nelfinavir, and Their Potential Usage for Combination Treatment

Number of pages: 36 Posted: 23 Jun 2020
National Institute of Infectious Diseases - Department of Virology II, National Institute of Infectious Diseases - Department of Virology II, National Institute of Infectious Diseases - Department of Virology II, National Institute of Infectious Diseases - Department of Virology II, Kyushu University - Department of Biology, National Institute of Advanced Industrial Science and Technology (AIST) - Cellular and Molecular Biotechnology Research Institute, RIKEN Center for Biosystems Dynamics Research - Drug Discovery Structural Biology Platform Unit, Nagahama Institute of Bio-Science and Technology - Department of Bioscience, Nara Institute of Science and Technology - Graduate School of Science and Technology, Kyushu University - Department of Biology, Kyushu University - Department of Biology, Hokkaido University - Center for Research and Education on Drug Discovery, Kyushu University - Department of Virology, National Institute of Infectious Diseases - Department of Virology II, National Institute of Infectious Diseases - Department of Virology I, Indiana University Bloomington - Department of Epidemiology and Biostatistics, National Center for Global Health and Medicine - AIDS Clinical Center, Tokyo University of Science - Faculty of Pharmaceutical Sciences, Tokyo University of Science - Faculty of Pharmaceutical Sciences, Tokyo University of Science - Department of Applied Biological Science, National Institute of Infectious Diseases - Department of Pathology, RIKEN Center for Life Science Technologies - Division of Structural and Synthetic Biology, Kyushu University - Department of Virology, Hokkaido University - Laboratory of Biomolecular Science, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - Department of Virology II, National Institute of Infectious Diseases - Department of Virology I, University of Tokyo - International Research Center for Neurointelligence, Kyushu University - Department of Biology, National Institute of Infectious Diseases - Department of Virology III, University of Oxford - Nuffield Department of Medicine and National Institute of Infectious Diseases - Department of Virology II
Downloads 38 (1,209,354)

Abstract:

Loading...

coronavirus, SARS-CoV-2, COVID-19, antiviral, Nelfinavir, Cepharanthine, protease, spike, in silico